Structures of human plasma β–factor XIIa cocrystallized with potent inhibitors-Reference-Cited by-同舟云学术

Structures of human plasma β–factor XIIa cocrystallized with potent inhibitors

Published:2018-03-08 Issue:5 Volume:2 Page:549-558
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Dementiev Alexey¹,Silva Abel²,Yee Calvin²,Li Zhe²,Flavin Michael T.¹,Sham Hing²,Partridge James R.²

Affiliation:

1. Shamrock Structures, LLC, Woodridge, IL; and

2. Global Blood Therapeutics, Inc, South San Francisco, CA

Abstract

Key Points The first crystal structure of human plasma β-FXIIa in its active state is presented. The conformational lability of FXIIa is discussed. These novel structural data provide molecular insight into β-FXIIa interaction with its substrates and inhibitors.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/5/549/880517/advances016337.pdf

Reference38 articles.

1. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes;Colman;Blood,1997

2. Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies;Samuel;J Biol Chem,1992

3. Contact activation (kallikrein-kinin) pathway: multiple physiologic and pathophysiologic activities;Colman,2006

4. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo;Müller;Cell,2009

5. Intrinsic pathway of coagulation and arterial thrombosis;Gailani;Arterioscler Thromb Vasc Biol,2007

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural basis for the inhibition of βFXIIa by garadacimab;Structure;2024-07

2. Development of supramolecular anticoagulants with on-demand reversibility;Nature Biotechnology;2024-04-30

3. Discovery of α-Amidobenzylboronates as Highly Potent Covalent Inhibitors of Plasma Kallikrein;ACS Medicinal Chemistry Letters;2024-03-28

4. New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants;ACS Omega;2024-02-22

5. Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation;Frontiers in Pharmacology;2023-12-19